Want to see BICX full AI Analyst Report?
BICX Stock Chart & Stats
$0.22
$0.05(20.00%)
At close: 4:00 PM EDT
$0.22
$0.05(20.00%)
Day’s Range― - ―
52-Week Range$0.15 - $1.28
Previous CloseN/A
Volume543.00
Average Volume (3M)2.01K
Market Cap
$7.44M
Enterprise Value$17.35
Total Cash (Recent Filing)$21.24K
Total Debt (Recent Filing)$7.66M
Price to Earnings (P/E)―
Beta0.14
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding29,758,177
10 Day Avg. Volume483
30 Day Avg. Volume2,008
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)-0.48
Price to Sales (P/S)6.75
P/FCF Ratio-2.34
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High Gross MarginA gross margin near 71% indicates that the company’s products and services can generate attractive contribution economics before operating costs. If revenue expands enough to cover the current cost base, this margin profile could support meaningful operating leverage and improve future profitability.
Addiction Treatment FocusBioCorRx operates in a healthcare niche addressing addiction treatment and recovery support, which gives its business a clearly defined social and clinical purpose. Continued demand for recovery-related offerings could provide a durable market rationale for its products, services, and affiliated programs.
Improving Free Cash Flow TrendAlthough free cash flow remains negative, the year-over-year improvement suggests some progress in the company’s cash-consumption profile. Sustaining and extending that direction could reduce financing pressure over time, especially if operating losses narrow and revenue stabilizes or grows.
Bears Say
Severe UnprofitabilityLosses are extremely large relative to the company’s small revenue base, showing that current operations do not yet support the cost structure. Persistent negative earnings reduce internally generated capital, limit reinvestment capacity, and make a durable path to profitability dependent on substantial improvement.
Negative Equity And Solvency RiskThe substantial equity deficit indicates a structurally weak balance sheet and limited financial flexibility. Combined with outstanding debt, it raises the risk that BioCorRx may need recapitalization or other external funding, potentially constraining strategic choices and increasing pressure on future shareholders.
Small And Declining Revenue BaseRevenue remains very small and declined from the prior period, providing an insufficient base to absorb the company’s operating costs and losses. Without sustained commercial expansion, BioCorRx may struggle to achieve scale, improve margins after operating expenses, or reduce reliance on outside financing.
BioCorRx News
BICX FAQ
What was BioCorRx Inc’s price range in the past 12 months?
BioCorRx Inc lowest stock price was $0.15 and its highest was $1.28 in the past 12 months.
What is BioCorRx Inc’s market cap?
BioCorRx Inc’s market cap is $7.44M.
When is BioCorRx Inc’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were BioCorRx Inc’s earnings last quarter?
Currently, no data Available
Is BioCorRx Inc overvalued?
According to Wall Street analysts BioCorRx Inc’s price is currently Overvalued.
Does BioCorRx Inc pay dividends?
BioCorRx Inc does not currently pay dividends.
What is BioCorRx Inc’s EPS estimate?
BioCorRx Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BioCorRx Inc have?
BioCorRx Inc has 29,758,177 shares outstanding.
What happened to BioCorRx Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of BioCorRx Inc?
Currently, no hedge funds are holding shares in BICX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BioCorRx Inc
BioCorRx Inc. (BICX), through its various operations, is dedicated to creating and delivering therapeutic solutions for individuals struggling with substance dependence and related health conditions across the United States. Among its core offerings is the BioCorRx recovery program, an innovative, non-addictive treatment model. This program uniquely combines proprietary naltrexone implants with extensive counseling services to support patient recovery. Additionally, the company provides the UnCraveRx weight management program, a medically supported initiative designed to curb food cravings. This program integrates pharmacological assistance with readily available virtual support focusing on lifestyle adjustments, fitness, and nutritional guidance. Looking to the future, BioCorRx is actively advancing its product pipeline. This includes BICX101, an injectable naltrexone product, and BICX104, an implantable naltrexone device, both currently under development for the specific treatment of opioid addiction and alcoholism. The company's programs are made available to patients through a network of healthcare providers, independent licensed clinics, and other qualified healthcare professionals. Originally established as Fresh Start Private Management, Inc., the organization officially rebranded as BioCorRx Inc. in January 2014. Its corporate headquarters are situated in Anaheim, California.
Technical Analysis
XWELL
―
NewGenIvf Group
―
Mobile-health Network Solutions Class A
―
Basel Medical Group Ltd
―
20/20 Biolabs, Inc.
―